Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798083 | 0.75 | EGFR (0.47) | EGFRNOS1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29618252 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2007641 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL3820499 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4036487 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL277181 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19716355 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18810410 | 0.75 | EGFR (0.47) | EGFRNOS1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1261572 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL277182 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840537-B2 | Preparation and application of a 5-bromoquinazoline derivative | HEFEI UNIVERSITY OF TECHNOLOGY (CN) | 2023-12-12 | — | — | US | claimed |
| US-20220135578-A1 | Preparation and Application of A 5-bromoquinazoline Derivative | HEFEI UNIVERSITY OF TECHNOLOGY (CN) | 2022-05-05 | — | — | US | claimed |
| CN-112300178-B | Preparation and application of 5-bromoquinazoline derivative | 合肥工业大学 | 2021-09-10 | — | — | CN | claimed |
| CN-112300178-A | Preparation and application of 5-bromoquinazoline derivative | 合肥工业大学 | 2021-02-02 | — | — | CN | claimed |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024182788-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024112201-A1 | DNA GYRASE INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024079072-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | BIODOL THERAPEUTICS (FR) | 2024-04-18 | — | — | WO | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-2896620-A1 | ALKYNYL HETEROAROMATIC RING COMPOUND AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| CN-102753535-A | Quinazolines as Potassium Channel Inhibitors | BRISTOL MYERS SQUIBB CO | 2012-10-24 | — | — | CN | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2473487-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | EGFR 4850/4885BACE1 3905/4885NOS1 2702/4885 |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNH3, KCNQ4 | EGFR 4838/4885BACE1 3648/4885NOS1 2571/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | EGFR 1239/4885BACE1 4325/4885NOS1 3815/4885 |
| US-20220135578-A1 | Preparation and Application of A 5-bromoquinazoline Derivative | BRI3BP, BRSK1, BRDT | EGFR 811/4885BACE1 2274/4885NOS1 736/4885 |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | ALK, CYP3A43, ALKBH3 | EGFR 738/4885BACE1 420/4885NOS1 389/4885 |
| US-11840537-B2 | Preparation and application of a 5-bromoquinazoline derivative | BRI3BP, BRSK1, BRDT | EGFR 811/4885BACE1 2274/4885NOS1 736/4885 |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | EGFR 4850/4885BACE1 3905/4885NOS1 2702/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | EGFR 656/4885BACE1 4464/4885NOS1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.